ACGN — Aceragen Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $3.20m
- $1.08m
- $4.86m
Brief: Aceragen Inc To Delist From The Nasdaq Stock Market
Aceragen Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Aceragen Board Determined It Is In Best Interests Of Co,To Effect Transfer,Assignment Of All Of Co's Assets To Assignee
Aceragen Inc reports results for the quarter ended in March - Earnings Summary
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Brief: Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Brief: Aceragen Inc said Board Approved Reduction of About 80% Of Co's Employees
Aceragen Inc expected to post a loss of $2.12 a share - Earnings Preview
Brief: Aceragen Announces Recommendation Of Data Monitoring Committee In Terra Study
Brief: Idera Pharmaceuticals Announces Name Change To Aceragen, Inc. And Provides Near-Term Strategic Outlook
Brief: Idera Pharmaceuticals Inc Says By Decision Dated Jan 10, Nasdaq Panel Granted Co Extension Until Jan 20, To Complete Shareholder Meeting & Attendant Transactions
Brief: Idera Pharmaceuticals Inc Receives Nasdaq Notice For Not Being Compliant With The Minimum Bid Price Requirement
Brief: Idera Pharmaceuticals Reports Third Quarter 2022 Financial Results